Peptides bound to cell surface MHC molecules allow the immune system to recognize intracellular pathogens and tumor-derived peptides. Each MHC allele has a distinct peptide binding motif which favours certain amino acids at particular points in a sequence. Complete Omics scientists developed and have been keeping on improving a set of methods that could capture essentially all MHC molecules and harvest the peptides presented by those MHC molecules. Through our unique neoantigen detection and quantification platform, we could help you validate neoantigens that are actually presented on the cell surface thus serving as your potential druggable targets before you investing hundreds of thousands of dollars into therapeutic method development, and provide you accurate quantification values for your neoantigen targets. Prediction methods only can predict the binding affinity, and higher affinity does not mean a valid presentation. Our Valid-NEO pipeline is completely PREDICTION-FREE, and we DIRECTLY SEE the data and let the data talk. WE DO NOT GUESS (PREDICT).

There are several milestone papers published by our team demonstrating early versions of our technique (such as MANA-SRM). Our current Valid-NEO pipeline represents a giant leap forward. Please click on the papers below for additional technical details:

Direct Detection and Quantification of Neoantigens. Cancer Immunol Res . 2019 Nov;7(11):1748-1754.

Bispecific antibodies targeting mutant RAS neoantigens. Sci Immunol . 2021 Mar 1;6(57):eabd5515.

Targeting a neoantigen derived from a common TP53 mutation. Science . 2021 Mar 5;371(6533):eabc8697.

Data analysis, including data validation, visualization and quantification, are performed with commercial softwares and Complete Omics’ unique R packages and scripts. Report will be sent to you in Excel format as well as a summary in PDF format. We will also provide you any details you need for your papers’ MATERIALS AND METHODS section. We will make sure you understand your result and help you with your paper writing with free follow-up services.

Sample types we accept:

1, Tissue culture cell pellets

2, Tumor tissue chunk

3, Clinical Biopsy Samples (minimal 5 mg tissue)

4, Biofluids, such as plasma*, serum*, saliva, tear, etc.

*We provide High Abundance Protein Depletion Service to significantly (100-500 folds) increase the depth of your biofluid proteomics analysis by removing top abundant proteins from your samples. Read more for details​.

5, FFPE blocks

6, Customized sample types (please contact us to discuss)

Collaboration with Baylor College of Medicine

Jan 19, 2022 | BALTIMORE –  Complete Omics’ Clinical Proteomics team announced a collaboration with Professor Andras Attila Heczey and his team from Baylor College of Medicine on a clinical proteomics…

Read more

Collaboration with Washington University in St. Louis

Jan 12, 2022 | BALTIMORE –  Complete Omics’ Clinical Proteomics team announced a collaboration with Professor Marco Sardiello and his team from Washington University in St. Louis on a clinical proteomics…

Read more

Happy Holidays from Complete Omics!

December 23, 2021 | BALTIMORE – Dear Team Members and Friends: 2021 has been an exciting year for Complete Omics – – we brought dramatic improvements to biomedical sciences and…

Read more

Some of our impacts